Small molecule antagonists of chemokine receptors as emerging anti-HIV agents

Bibliography

• TOMARAS GD, GREENBERG ML: Mechanisms for HIV-1 entry: current strategies to interfere with this step. Gun: Infect. Dis. Rep. (2001) 3:93–99.
   Google Scholar
• ECKERT DM, KIM PS: Mechanisms of viral membrane fusion and its inhibition. Anna Rev Biochem. (2001) 70:777–810.
   PubMed Web of Science ®Google Scholar
• ••Comprehensive review on the state-of-the-art of the biochemical mechanisms of viral fusion, as well as the steps to be inhibited for developing therapeutic agents/vaccines effective against HIV or influenza viruses.
   Google Scholar
• BLAIR WS, UN PF, MEANWELL NA, WALLACE OB: HIV-1 entry - an expanding portal for drug discovery. Dug Dev. Today (2000) 5:183–194.
   PubMed Web of Science ®Google Scholar
• TURPIN JA, HOWARD OMZ: Inhibitors of HIV cellular fusion. Expert Opin. Ther. Patents (2000) 10:1899–1909.
   Google Scholar
• D'SOUZA MP, CAIRNS JS, PLAEGER SF: Current evidence and future directions for targeting HIV-1 entry. I Am. Med. Ass (2000) 284:215–222.
   PubMed Web of Science ®Google Scholar
• KWONG PD, WYATT R, ROBINSON J, SWEETS RW, SODROSKI J, HENDRICKSON WA: Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature (1998) 393:648–659.
   PubMed Web of Science ®Google Scholar
• ••The x-ray characterization for theinteraction of HIV-1 gp120 with the CD4 receptor.
   Google Scholar
• STANTCHEV TS, BRODER CC: Human immunodeficiency virus type-1 and chemokines: beyond competition for common cellular receptors. Cytokine Growth Factors Rev (2001) 12:219–243.
   PubMed Web of Science ®Google Scholar
• ••Excellent review on the chemokinecoreceptors used by HIV-1.
   Google Scholar
• ROOT MJ, KAY MS, KIM PS: Design of an HIV-1 entry inhibitor. Science (2001) 291:884–888.
   PubMed Web of Science ®Google Scholar
• ••An excellent approach for designing potententry inhibitors.
   Google Scholar
• DOWD CS, ZHANG W, LI C, CHAIKENIM: From receptor recognition mechanisms to bioinspired mimetic antagonists in HIV-1/cell docking. j Chromatography B (2001) 753:327–335.
   PubMedGoogle Scholar
• DONG XN, XIAO Y, DIERICH MP, CHEN YH: N- and C-domains of HIV-1 gp41: mutation, structure and functions. Immurrol Lett. (2001) 75:215–220.
   PubMedGoogle Scholar
• NAGASHIMA KA, THOMPSON DAD, ROSENFIELD SI, MADDON PJ, DRAGIC T, OLSON WC: HIV type 1 entry inhibitors PRO 542 and T-20 are potently synergistic in blocking virus-cell and cell-cell fusion. j Infect. Dis. (2001) 183:1121–1125.
   PubMed Web of Science ®Google Scholar
• TAMAMURA H, OMAGARI A, OISHI S, etal.: Pharmacophore identification of a specific CXCR4 inhibitor, T140, leads to development of effective anti-HIV-1 agents with very high selectivity indexes. Bioorg. Med. Chem. Lett. (2000) 10:2633–2637.
   Google Scholar
• DORN CP, FINKE PE, OATES B et al: Antagonists of the human CCR5 receptor as anti-HIV-1. Part 1: discovery and initial structure - activity relationships for 1-amino- 2-phenyl-4-(piperidin-1-yl)butanes. Bioorg. Med. Chem. Lett. (2001) 11:259–264.
   Google Scholar
• FINKE PE, MEURER LC, OATES B et al:Antagonists of the human CCR5 receptor as anti-HIV-1. Part 2: structure - activity relationships for substituted 2-aryl-1- UV-(methyl)-N-phenylsulfonyl)aminc4-4-(piperidin- 1-yl)butanes. Bioorg. Med. Chem. Lett. (2001) 11:265–270.
   Google Scholar
• IKEMOTO T, NISHIGUCHI A, MITSUDERA H, WAKIMASU M, TOMIMATSU K: Convenient efficient synthesis of TAK-779, a nonpeptide CCR5 antagonist: development of preparation of various ammonium salts using trialkylphosphite and N-halogeno-succinimide. Tetrahedron (2001) 11:1525–1529.
   Google Scholar
• BLANCO J, BARRETINA J, HENSON G etal.: The CXCR4 antagonist AMD3100 effeciently inhibits cell-surface-expressed HIV type 1 envelope-induced apoptosis. Antimicrob. Agents Chemother. (2000) 44:51–56.
   Google Scholar
• DE CLERCQ E: Molecular targets for antiviral agents. j Pharmacol Esp. Ther. (2001) 297:1–10.
   PubMed Web of Science ®Google Scholar
• MORI T, BOYD MR: Cyanovirin-N, a potent HIV-inactivating protein, blocks both CD4-dependent and CD4-independent binding of soluble gp120 to target cells, inhibits sCD4-induced binding of sgp120 to cell-associated CXCR4, and dissociates bound sgp120 from target cells. Antimicrob. Agents Chemother. (2001) 45:664–672.
   PubMed Web of Science ®Google Scholar
• HENDRIX CW, FLEXNER C, MCFARLAND RT etal.: Pharmacokinetics and safety of AMD3100, a novel antagonist of the CXCR4 chemokine receptor in human volunteers. Antimicrob. Agents Chemother. (2000) 44:1667–1673.
   Google Scholar
• DE CLERCQ E: Inhibition of HIV infection by bicyclams, highly potent and specific CXCR4 antagonists. Mal Pharmacol (2000) 57:833–839.
   PubMed Web of Science ®Google Scholar
• DORANZ BJ, FILION LG, DIAZ-MITOMA F: Safe use of the CXCR4 inhibitor ALX40-4c in humans. AIDS Res. Hum. Retroviruses (2001) 17:475–486.
   PubMed Web of Science ®Google Scholar
• AnorMED discontinues clinical development program for AMD-3100 in HIV. Press release. AnorMED, Vancouver, Canada (25th May 2001).
   Google Scholar
• SHIRAISHI M, ARAMAKI Y, SETO M et al.: Discovery of novel, potent, and selective small-molecule CCR5 antagonists as anti-HIV-1 agents: synthesis and biological evaluation of anilide derivatives with a quaternary ammonium moiety. j Med. Chem. (2000) 43:2049–2063.
   PubMed Web of Science ®Google Scholar
• ••Discloses the synthesis and biologicalactivity of TAK-779, a potent CCR5 antagonist.
   Google Scholar
• DRAGIC T, TRKOLA A, THOMPSON DAD et al: A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5. Proc. Natl. Acad. Sri. USA (2000) 97:5639–5644.
   PubMed Web of Science ®Google Scholar
• SCOZZAFAVA A, BRIGANTI F, ILIES MA, SUPURAN CT: Carbonic anhydrase inhibitors: synthesis of membrane- impermeant low molecular weight sulfonamides possessing in vivo selectivity for the membrane-bound versus the cytosolic isozymes. j Med. Chem. (2000) 43:292–300.
   PubMed Web of Science ®Google Scholar
• SUPURAN CT, SCOZZAFAVA A, ILIES MA, BRIGANTI F: Carbonic anhydrase inhibitors: synthesis of sulfonamides incorporating 2,4,6-trisubstituted-pyridinium-ethylcarboxamido moieties possessing membrane-impermeability and in vivo selectivity for the membrane-bound (CA IV) versus the cytosolic (CAI and CA II) isozymes. j Enz. lithib. (2000) 15:381–401.
   PubMed Web of Science ®Google Scholar
• CASCIERI MA, SPRINGER MS: The chemokine/chemokine receptor family: potential progress for therapeutic intervention. Curr. Opin. Chem. Biol. (2000) 4:420–427.
   PubMed Web of Science ®Google Scholar
• OGDEN RT, FLEXNER CW: Protease inhibitors in the treatment of AIDS. Marcel Dekker, New York, USA (2001).
   Google Scholar
• RICHMAN DD: HIV chemotherapy. Nature (2001) 410:995–1001.
   PubMed Web of Science ®Google Scholar
• WEISS RA: Gulliver's travels in HIV land. Nature (2001) 410:963–967.
   PubMedGoogle Scholar
• NABEL GJ: Challenges and opportunities for development of an AIDS vaccine. Nature (2001) 410:1002–1007.
   PubMed Web of Science ®Google Scholar
• SCOZZAFAVA A, MASTROLORENZO A, SUPURAN CT: Agents that target cysteine residues of biomolecules and their therapeutic potential. Expert Opin Ther. Patents (2001) 11:765–787.
   Web of Science ®Google Scholar